Effect of a fourth‐generation transcatheter valve enhanced skirt on paravalvular leak

Objectives The aim of this study was to assess the 30 day incidence of paravalvular leak (PVL) and need for aortic valve reintervention of a fourth generation balloon expandable transcatheter valve with enhanced skirt (4G‐BEV) (SAPIEN 3 Ultra) compared with a third generation balloon expandable tran...

Full description

Saved in:
Bibliographic Details
Published in:Catheterization and cardiovascular interventions 2021-04, Vol.97 (5), p.895-902
Main Authors: Welle, Garrett A., El‐Sabawi, Bassim, Thaden, Jeremy J., Greason, Kevin L., Klarich, Kyle W., Nkomo, Vuyisile T., Alkhouli, Mohamad A., Guerrero, Mayra E., Crestanello, Juan A., Holmes, David R., Rihal, Charanjit S., Eleid, Mackram F.
Format: Article
Language:English
Subjects:
Aortic valve
aortic valve disease
Balloon treatment
Calcium
Echocardiography
interventional devices/innovation
transcatheter valve implantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3537-9faccfd8c282b74f725ea8b67b3712e5e21e0f770d0776292ac8c0007d1ae2163
cites cdi_FETCH-LOGICAL-c3537-9faccfd8c282b74f725ea8b67b3712e5e21e0f770d0776292ac8c0007d1ae2163
container_end_page 902
container_issue 5
container_start_page 895
container_title Catheterization and cardiovascular interventions
container_volume 97
creator Welle, Garrett A.
El‐Sabawi, Bassim
Thaden, Jeremy J.
Greason, Kevin L.
Klarich, Kyle W.
Nkomo, Vuyisile T.
Alkhouli, Mohamad A.
Guerrero, Mayra E.
Crestanello, Juan A.
Holmes, David R.
Rihal, Charanjit S.
Eleid, Mackram F.
description Objectives The aim of this study was to assess the 30 day incidence of paravalvular leak (PVL) and need for aortic valve reintervention of a fourth generation balloon expandable transcatheter valve with enhanced skirt (4G‐BEV) (SAPIEN 3 Ultra) compared with a third generation balloon expandable transcatheter valve (3G‐BEV) (SAPIEN 3). Background The incidence of PVL has steadily declined with iterative improvements in transcatheter aortic valve replacement (TAVR) technology and implantation strategies. Methods Patients who underwent TAVR at Mayo Clinic from 7/2018 to 7/2019 were included in a prospective institutional registry. 4G‐BEV has been utilized since 2/2019, and, after this date, 3G‐BEV and 4G‐BEV were simultaneously used. 4G‐BEV had three sizes (20, 23, and 26 mm) while 3G‐BEV included four sizes (20, 23, 26, and 29 mm). Both cohorts were evaluated at 30 days post‐TAVR with a transthoracic echocardiogram to assess for PVL. Results A total of 260 consecutive patients were included. Of these, 101 patients received a 4G‐BEV and 159 patients received a 3G‐BEV. There were more females (p = .0005) and a lower aortic valve calcium score (p = .02) in the 4G‐BEV cohort at baseline. Age, STS risk score, NYHA Class, and aortic valve mean gradient did not differ between groups. 4G‐BEV was associated with a lower incidence of mild PVL (10.8 vs. 36.5%; p 
doi_str_mv 10.1002/ccd.29317
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2449179883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2512270566</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-9faccfd8c282b74f725ea8b67b3712e5e21e0f770d0776292ac8c0007d1ae2163</originalsourceid><addsrcrecordid>eNp1kM9OwzAMhyMEYmNw4AVQJC5w2EjctWmPaPyVkLiA4BZ5qcPKunYkLWg3HoFn5EnI2OCAxMmW_PmT_WNsX4qBFAJOjMkHkEVSbbCujAH6CpLHzXUvs2HSYTvePwshsgSybdaJIgEgpeqyh3NryTS8thy5rVvXTD7fP56oIodNUVe8cVh5g82EGnL8FctX4lRNsDKUcz8tXNit-BwdLmdtiY6XhNNdtmWx9LS3rj12f3F-N7rq39xeXo9Ob_omiiPVzywaY_PUQApjNbQKYsJ0nKhxpCRQTCBJWKVELpQKtwOa1IQ_VC4xzJKox45W3rmrX1ryjZ4V3lBZYkV16zUMh5lUWZpGAT38gz6Hf6twnYZYAigRJ0vh8YoyrvbekdVzV8zQLbQUepm2Dmnr77QDe7A2tuMZ5b_kT7wBOFkBb0VJi_9NejQ6Wym_APs2iVk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512270566</pqid></control><display><type>article</type><title>Effect of a fourth‐generation transcatheter valve enhanced skirt on paravalvular leak</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Welle, Garrett A. ; El‐Sabawi, Bassim ; Thaden, Jeremy J. ; Greason, Kevin L. ; Klarich, Kyle W. ; Nkomo, Vuyisile T. ; Alkhouli, Mohamad A. ; Guerrero, Mayra E. ; Crestanello, Juan A. ; Holmes, David R. ; Rihal, Charanjit S. ; Eleid, Mackram F.</creator><creatorcontrib>Welle, Garrett A. ; El‐Sabawi, Bassim ; Thaden, Jeremy J. ; Greason, Kevin L. ; Klarich, Kyle W. ; Nkomo, Vuyisile T. ; Alkhouli, Mohamad A. ; Guerrero, Mayra E. ; Crestanello, Juan A. ; Holmes, David R. ; Rihal, Charanjit S. ; Eleid, Mackram F.</creatorcontrib><description>Objectives The aim of this study was to assess the 30 day incidence of paravalvular leak (PVL) and need for aortic valve reintervention of a fourth generation balloon expandable transcatheter valve with enhanced skirt (4G‐BEV) (SAPIEN 3 Ultra) compared with a third generation balloon expandable transcatheter valve (3G‐BEV) (SAPIEN 3). Background The incidence of PVL has steadily declined with iterative improvements in transcatheter aortic valve replacement (TAVR) technology and implantation strategies. Methods Patients who underwent TAVR at Mayo Clinic from 7/2018 to 7/2019 were included in a prospective institutional registry. 4G‐BEV has been utilized since 2/2019, and, after this date, 3G‐BEV and 4G‐BEV were simultaneously used. 4G‐BEV had three sizes (20, 23, and 26 mm) while 3G‐BEV included four sizes (20, 23, 26, and 29 mm). Both cohorts were evaluated at 30 days post‐TAVR with a transthoracic echocardiogram to assess for PVL. Results A total of 260 consecutive patients were included. Of these, 101 patients received a 4G‐BEV and 159 patients received a 3G‐BEV. There were more females (p = .0005) and a lower aortic valve calcium score (p = .02) in the 4G‐BEV cohort at baseline. Age, STS risk score, NYHA Class, and aortic valve mean gradient did not differ between groups. 4G‐BEV was associated with a lower incidence of mild PVL (10.8 vs. 36.5%; p &lt; .0001) and moderate PVL (0 vs. 5.8%) compared to the 3G‐BEV at 30 days. There was no association between PVL and valve size in either cohort. Conclusions Utilization of 4G‐BEV is associated with reduced PVL at 30 days post‐TAVR compared with 3G‐BEV.</description><identifier>ISSN: 1522-1946</identifier><identifier>EISSN: 1522-726X</identifier><identifier>DOI: 10.1002/ccd.29317</identifier><identifier>PMID: 33022117</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Aortic valve ; aortic valve disease ; Balloon treatment ; Calcium ; Echocardiography ; interventional devices/innovation ; transcatheter valve implantation</subject><ispartof>Catheterization and cardiovascular interventions, 2021-04, Vol.97 (5), p.895-902</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-9faccfd8c282b74f725ea8b67b3712e5e21e0f770d0776292ac8c0007d1ae2163</citedby><cites>FETCH-LOGICAL-c3537-9faccfd8c282b74f725ea8b67b3712e5e21e0f770d0776292ac8c0007d1ae2163</cites><orcidid>0000-0001-6082-5379 ; 0000-0001-5252-4293 ; 0000-0001-5331-1900 ; 0000-0002-0037-0373</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33022117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Welle, Garrett A.</creatorcontrib><creatorcontrib>El‐Sabawi, Bassim</creatorcontrib><creatorcontrib>Thaden, Jeremy J.</creatorcontrib><creatorcontrib>Greason, Kevin L.</creatorcontrib><creatorcontrib>Klarich, Kyle W.</creatorcontrib><creatorcontrib>Nkomo, Vuyisile T.</creatorcontrib><creatorcontrib>Alkhouli, Mohamad A.</creatorcontrib><creatorcontrib>Guerrero, Mayra E.</creatorcontrib><creatorcontrib>Crestanello, Juan A.</creatorcontrib><creatorcontrib>Holmes, David R.</creatorcontrib><creatorcontrib>Rihal, Charanjit S.</creatorcontrib><creatorcontrib>Eleid, Mackram F.</creatorcontrib><title>Effect of a fourth‐generation transcatheter valve enhanced skirt on paravalvular leak</title><title>Catheterization and cardiovascular interventions</title><addtitle>Catheter Cardiovasc Interv</addtitle><description>Objectives The aim of this study was to assess the 30 day incidence of paravalvular leak (PVL) and need for aortic valve reintervention of a fourth generation balloon expandable transcatheter valve with enhanced skirt (4G‐BEV) (SAPIEN 3 Ultra) compared with a third generation balloon expandable transcatheter valve (3G‐BEV) (SAPIEN 3). Background The incidence of PVL has steadily declined with iterative improvements in transcatheter aortic valve replacement (TAVR) technology and implantation strategies. Methods Patients who underwent TAVR at Mayo Clinic from 7/2018 to 7/2019 were included in a prospective institutional registry. 4G‐BEV has been utilized since 2/2019, and, after this date, 3G‐BEV and 4G‐BEV were simultaneously used. 4G‐BEV had three sizes (20, 23, and 26 mm) while 3G‐BEV included four sizes (20, 23, 26, and 29 mm). Both cohorts were evaluated at 30 days post‐TAVR with a transthoracic echocardiogram to assess for PVL. Results A total of 260 consecutive patients were included. Of these, 101 patients received a 4G‐BEV and 159 patients received a 3G‐BEV. There were more females (p = .0005) and a lower aortic valve calcium score (p = .02) in the 4G‐BEV cohort at baseline. Age, STS risk score, NYHA Class, and aortic valve mean gradient did not differ between groups. 4G‐BEV was associated with a lower incidence of mild PVL (10.8 vs. 36.5%; p &lt; .0001) and moderate PVL (0 vs. 5.8%) compared to the 3G‐BEV at 30 days. There was no association between PVL and valve size in either cohort. Conclusions Utilization of 4G‐BEV is associated with reduced PVL at 30 days post‐TAVR compared with 3G‐BEV.</description><subject>Aortic valve</subject><subject>aortic valve disease</subject><subject>Balloon treatment</subject><subject>Calcium</subject><subject>Echocardiography</subject><subject>interventional devices/innovation</subject><subject>transcatheter valve implantation</subject><issn>1522-1946</issn><issn>1522-726X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kM9OwzAMhyMEYmNw4AVQJC5w2EjctWmPaPyVkLiA4BZ5qcPKunYkLWg3HoFn5EnI2OCAxMmW_PmT_WNsX4qBFAJOjMkHkEVSbbCujAH6CpLHzXUvs2HSYTvePwshsgSybdaJIgEgpeqyh3NryTS8thy5rVvXTD7fP56oIodNUVe8cVh5g82EGnL8FctX4lRNsDKUcz8tXNit-BwdLmdtiY6XhNNdtmWx9LS3rj12f3F-N7rq39xeXo9Ob_omiiPVzywaY_PUQApjNbQKYsJ0nKhxpCRQTCBJWKVELpQKtwOa1IQ_VC4xzJKox45W3rmrX1ryjZ4V3lBZYkV16zUMh5lUWZpGAT38gz6Hf6twnYZYAigRJ0vh8YoyrvbekdVzV8zQLbQUepm2Dmnr77QDe7A2tuMZ5b_kT7wBOFkBb0VJi_9NejQ6Wym_APs2iVk</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Welle, Garrett A.</creator><creator>El‐Sabawi, Bassim</creator><creator>Thaden, Jeremy J.</creator><creator>Greason, Kevin L.</creator><creator>Klarich, Kyle W.</creator><creator>Nkomo, Vuyisile T.</creator><creator>Alkhouli, Mohamad A.</creator><creator>Guerrero, Mayra E.</creator><creator>Crestanello, Juan A.</creator><creator>Holmes, David R.</creator><creator>Rihal, Charanjit S.</creator><creator>Eleid, Mackram F.</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6082-5379</orcidid><orcidid>https://orcid.org/0000-0001-5252-4293</orcidid><orcidid>https://orcid.org/0000-0001-5331-1900</orcidid><orcidid>https://orcid.org/0000-0002-0037-0373</orcidid></search><sort><creationdate>20210401</creationdate><title>Effect of a fourth‐generation transcatheter valve enhanced skirt on paravalvular leak</title><author>Welle, Garrett A. ; El‐Sabawi, Bassim ; Thaden, Jeremy J. ; Greason, Kevin L. ; Klarich, Kyle W. ; Nkomo, Vuyisile T. ; Alkhouli, Mohamad A. ; Guerrero, Mayra E. ; Crestanello, Juan A. ; Holmes, David R. ; Rihal, Charanjit S. ; Eleid, Mackram F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-9faccfd8c282b74f725ea8b67b3712e5e21e0f770d0776292ac8c0007d1ae2163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aortic valve</topic><topic>aortic valve disease</topic><topic>Balloon treatment</topic><topic>Calcium</topic><topic>Echocardiography</topic><topic>interventional devices/innovation</topic><topic>transcatheter valve implantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Welle, Garrett A.</creatorcontrib><creatorcontrib>El‐Sabawi, Bassim</creatorcontrib><creatorcontrib>Thaden, Jeremy J.</creatorcontrib><creatorcontrib>Greason, Kevin L.</creatorcontrib><creatorcontrib>Klarich, Kyle W.</creatorcontrib><creatorcontrib>Nkomo, Vuyisile T.</creatorcontrib><creatorcontrib>Alkhouli, Mohamad A.</creatorcontrib><creatorcontrib>Guerrero, Mayra E.</creatorcontrib><creatorcontrib>Crestanello, Juan A.</creatorcontrib><creatorcontrib>Holmes, David R.</creatorcontrib><creatorcontrib>Rihal, Charanjit S.</creatorcontrib><creatorcontrib>Eleid, Mackram F.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Catheterization and cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Welle, Garrett A.</au><au>El‐Sabawi, Bassim</au><au>Thaden, Jeremy J.</au><au>Greason, Kevin L.</au><au>Klarich, Kyle W.</au><au>Nkomo, Vuyisile T.</au><au>Alkhouli, Mohamad A.</au><au>Guerrero, Mayra E.</au><au>Crestanello, Juan A.</au><au>Holmes, David R.</au><au>Rihal, Charanjit S.</au><au>Eleid, Mackram F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of a fourth‐generation transcatheter valve enhanced skirt on paravalvular leak</atitle><jtitle>Catheterization and cardiovascular interventions</jtitle><addtitle>Catheter Cardiovasc Interv</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>97</volume><issue>5</issue><spage>895</spage><epage>902</epage><pages>895-902</pages><issn>1522-1946</issn><eissn>1522-726X</eissn><abstract>Objectives The aim of this study was to assess the 30 day incidence of paravalvular leak (PVL) and need for aortic valve reintervention of a fourth generation balloon expandable transcatheter valve with enhanced skirt (4G‐BEV) (SAPIEN 3 Ultra) compared with a third generation balloon expandable transcatheter valve (3G‐BEV) (SAPIEN 3). Background The incidence of PVL has steadily declined with iterative improvements in transcatheter aortic valve replacement (TAVR) technology and implantation strategies. Methods Patients who underwent TAVR at Mayo Clinic from 7/2018 to 7/2019 were included in a prospective institutional registry. 4G‐BEV has been utilized since 2/2019, and, after this date, 3G‐BEV and 4G‐BEV were simultaneously used. 4G‐BEV had three sizes (20, 23, and 26 mm) while 3G‐BEV included four sizes (20, 23, 26, and 29 mm). Both cohorts were evaluated at 30 days post‐TAVR with a transthoracic echocardiogram to assess for PVL. Results A total of 260 consecutive patients were included. Of these, 101 patients received a 4G‐BEV and 159 patients received a 3G‐BEV. There were more females (p = .0005) and a lower aortic valve calcium score (p = .02) in the 4G‐BEV cohort at baseline. Age, STS risk score, NYHA Class, and aortic valve mean gradient did not differ between groups. 4G‐BEV was associated with a lower incidence of mild PVL (10.8 vs. 36.5%; p &lt; .0001) and moderate PVL (0 vs. 5.8%) compared to the 3G‐BEV at 30 days. There was no association between PVL and valve size in either cohort. Conclusions Utilization of 4G‐BEV is associated with reduced PVL at 30 days post‐TAVR compared with 3G‐BEV.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>33022117</pmid><doi>10.1002/ccd.29317</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6082-5379</orcidid><orcidid>https://orcid.org/0000-0001-5252-4293</orcidid><orcidid>https://orcid.org/0000-0001-5331-1900</orcidid><orcidid>https://orcid.org/0000-0002-0037-0373</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1522-1946
ispartof Catheterization and cardiovascular interventions, 2021-04, Vol.97 (5), p.895-902
issn 1522-1946
1522-726X
language eng
recordid cdi_proquest_miscellaneous_2449179883
source Wiley-Blackwell Read & Publish Collection
subjects Aortic valve
aortic valve disease
Balloon treatment
Calcium
Echocardiography
interventional devices/innovation
transcatheter valve implantation
title Effect of a fourth‐generation transcatheter valve enhanced skirt on paravalvular leak
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A22%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20a%20fourth%E2%80%90generation%20transcatheter%20valve%20enhanced%20skirt%20on%20paravalvular%20leak&rft.jtitle=Catheterization%20and%20cardiovascular%20interventions&rft.au=Welle,%20Garrett%20A.&rft.date=2021-04-01&rft.volume=97&rft.issue=5&rft.spage=895&rft.epage=902&rft.pages=895-902&rft.issn=1522-1946&rft.eissn=1522-726X&rft_id=info:doi/10.1002/ccd.29317&rft_dat=%3Cproquest_cross%3E2512270566%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3537-9faccfd8c282b74f725ea8b67b3712e5e21e0f770d0776292ac8c0007d1ae2163%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2512270566&rft_id=info:pmid/33022117&rfr_iscdi=true